MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
BioMarin Pharmaceutical ROE Ratio 2011-2026 | BMRN
Annual ROE Ratio BioMarin Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.73 | 7.54 | 3.39 | 3.08 | -1.5 | 20.83 | -0.76 | -2.6 | -4.17 | -22.78 | -7.16 | -8.77 | -13.15 | -11.26 | -6.96 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.83 | -22.78 | -2.57 |
Quarterly ROE Ratio BioMarin Pharmaceutical
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.12 | 9.15 | 5.73 | 6.56 | 5.42 | 4.57 | 3.09 | 2.94 | 1.97 | 1.42 | 3.22 | 2.37 | 1.66 | 1.35 | -0.13 | 18.98 | 38.95 | 37.93 | 20.38 | 22.15 | 4.8 | 4.31 | -1.24 | -1.67 | -3.86 | -3.22 | -2.48 | -2.92 | -2.95 | -3.69 | -2.34 | -3.69 | -4.6 | -18.43 | -19.5 | -23.29 | -25.72 | -13.99 | -10.01 | -9.53 | -5.25 | -4.03 | -4.2 | -8.15 | -12.59 | -12.01 | -8.53 | -9.06 | -5.63 | -7.17 | -6.04 | -8.32 | -10.08 | -7.58 | -3.51 | -2.28 | -0.66 | -0.57 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 38.95 | -25.72 | -1.05 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 9.33 | 1.41 % | $ 603 M |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.87 | -2.13 % | $ 6.4 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.38 | 0.81 % | $ 3.71 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Galapagos NV
GLPG
|
-11.44 | $ 28.15 | 1.04 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
9.2 | $ 8.22 | 3.92 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
18.24 | $ 30.95 | -0.34 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 8.43 | -0.12 % | $ 76.1 M | USA |
 |
InflaRx N.V.
IFRX
|
-43.64 | $ 1.97 | -0.51 % | $ 152 M | Germany |
 |
Incyte Corporation
INCY
|
24.9 | $ 98.55 | -0.55 % | $ 19.2 B | USA |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.71 | 1.27 % | $ 1.74 M |  Canada |
 |
Innoviva
INVA
|
23.12 | $ 22.97 | -0.35 % | $ 1.55 B | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 104.02 | 2.41 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Jaguar Health
JAGX
|
286.68 | $ 7.34 | -6.79 % | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
4039.99 | $ 26.68 | 0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.45 | -2.68 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
9.59 | $ 8.16 | 0.68 % | $ 260 M |  Israel |
 |
Krystal Biotech
KRYS
|
16.8 | $ 260.24 | 0.11 % | $ 7.53 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-132.24 | $ 13.58 | 9.34 % | $ 1.8 B |  Australia |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-0.49 | $ 220.06 | -2.13 % | $ 4.02 B | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.94 | -1.67 % | $ 4.84 M | Israel |
 |
Liquidia Corporation
LQDA
|
-154.03 | $ 38.41 | 0.67 % | $ 3.31 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.08 | 0.62 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 23.15 | 3.49 % | $ 2.95 B | USA |